16 May 2022 AffyXell expands its strategic partnership with GenScript ProBio Investors | Therapeutics
11 May 2022 Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus Investors | Therapeutics
12 Apr 2022 Poster presented at the American Association for Cancer Research Annual Meeting available to download Investors | Therapeutics
08 Apr 2022 AffyXell partners with Biocytogen and the Korea Non-clinical Technology Support Center Investors | Therapeutics
29 Mar 2022 Avacta to present pre-clinical data on AVA6000 at the American Association for Cancer Research Annual Meeting Investors | Therapeutics
03 Feb 2022 Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin Investors | Therapeutics
18 Jan 2022 Avacta Selects Second pre|CISIONTM Pro-drug Candidate for Development Investors | Therapeutics
29 Nov 2021 Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000 Investors | Therapeutics